| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Lexicon Pharmaceuticals, Inc.
13D/A
LXRX · 528872302
|
39.4% |
5/8/2026
Event 4/30/2026
|
||||
| Invus, L.P. | 9.6% | |||||
| Invus Advisors, L.L.C. | 9.6% | |||||
| Invus Public Equities, L.P. | 1.7% | |||||
| Invus Public Equities Advisors, LLC | 1.7% | |||||
| Invus Global Management, LLC | 9.6% | |||||
| Siren, L.L.C. | 9.6% | |||||
| Avicenna Life Sci Master Fund LP | 0.3% | |||||
| Avicenna Life Sci Master GP LLC | 0.3% | |||||
| Invus US Partners LLC | 1.2% | |||||
| Ulys, L.L.C. | 1.6% | |||||
| Raymond Debbane | 11.7% | |||||
| Artal Participations S.a r.l. | 39.4% | |||||
| Artal International S.C.A. | 39.4% | |||||
| Artal International Management S.A. | 39.4% | |||||
| Artal Group S.A. | 39.4% | |||||
| Westend S.A. | 39.4% | |||||
| Stichting Administratiekantoor Westend | 39.4% | |||||
| Amaury Wittouck | 39.4% | |||||
| Schedule 13G · 28 securities · passive | ||||||
|
City Therapeutics, Inc.
13G
178782108
|
8.1% |
10/22/2026
Event 10/16/2026
|
||||
| Invus Public Equities, L.P. | 8.1% | |||||
| Invus Public Equities Advisors, LLC | 8.1% | |||||
| Invus Global Management, LLC | 8.1% | |||||
| Siren, L.L.C. | 8.1% | |||||
| Avicenna Life Sci Master Fund LP | 0.1% | |||||
| Avicenna Life Sci Master GP LLC | 0.1% | |||||
| Ulys, L.L.C. | 0.1% | |||||
| Raymond Debbane | 8.1% | |||||
|
Yarrow Bioscience, Inc.
13G
YARW · 92941V407
|
7.2% |
9/17/2026
Event 9/11/2026
|
||||
| Invus Public Equities, L.P. | 6.3% | |||||
| Invus Public Equities Advisors, LLC | 6.3% | |||||
| Invus Global Management, LLC | 6.3% | |||||
| Siren, L.L.C. | 6.3% | |||||
| Avicenna Life Sci Master Fund LP | 0.9% | |||||
| Avicenna Life Sci Master GP LLC | 0.9% | |||||
| Ulys, L.L.C. | 0.9% | |||||
| Raymond Debbane | 7.2% | |||||
|
enGene Therapeutics Inc.
13G/A
ENGN · 29286X101
|
9.3% |
8/13/2026
Event 6/30/2026
|
||||
| Invus Public Equities, L.P. | 8.2% | |||||
| Invus Public Equities Advisors, LLC | 8.2% | |||||
| Invus Global Management, LLC | 8.2% | |||||
| Siren, L.L.C. | 8.2% | |||||
| Avicenna Life Sci Master Fund LP | 1.2% | |||||
| Avicenna Life Sci Master GP LLC | 1.2% | |||||
| Ulys, L.L.C. | 1.2% | |||||
| Raymond Debbane | 9.3% | |||||
|
Nanobiotix S.A.
13G/A
NBTX · 63009J107
|
9.4% |
8/13/2026
Event 6/30/2026
|
||||
| Invus Public Equities, L.P. | 9.4% | |||||
| Invus Public Equities Advisors, LLC | 9.4% | |||||
| Invus Global Management, LLC | 9.4% | |||||
| Siren, L.L.C. | 9.4% | |||||
| Raymond Debbane | 9.4% | |||||
|
Silence Therapeutics plc
13G/A
SLN · 82686Q101
|
7.0% |
8/13/2026
Event 6/30/2026
|
||||
| Invus Public Equities, L.P. | 6.1% | |||||
| Invus Public Equities Advisors, LLC | 6.1% | |||||
| Invus Global Management, LLC | 6.1% | |||||
| Siren, L.L.C. | 6.1% | |||||
| Avicenna Life Sci Master Fund LP | 0.9% | |||||
| Avicenna Life Sci Master GP LLC | 0.9% | |||||
| Ulys, L.L.C. | 0.9% | |||||
| Raymond Debbane | 7.0% | |||||
|
Scholar Rock Holding Corporation
13G/A
SRRK · 80706P103
|
8.0% |
8/13/2026
Event 6/30/2026
|
||||
| Invus Public Equities, L.P. | 8.0% | |||||
| Invus Public Equities Advisors, LLC | 8.0% | |||||
| Invus Global Management, LLC | 8.0% | |||||
| Siren, L.L.C. | 8.0% | |||||
| Raymond Debbane | 8.0% | |||||
|
Abivax S.A.
13G/A
ABVX · 00370M103
|
6.0% |
8/13/2026
Event 6/30/2026
|
||||
| Invus Public Equities, L.P. | 6.0% | |||||
| Invus Public Equities Advisors, LLC | 6.0% | |||||
| Invus Global Management, LLC | 6.0% | |||||
| Siren, L.L.C. | 6.0% | |||||
| Avicenna Life Sci Master Fund LP | 0% | |||||
| Avicenna Life Sci Master GP LLC | 0% | |||||
| Ulys, L.L.C. | 0% | |||||
| Raymond Debbane | 6.0% | |||||
|
Hemab Therapeutics Holdings, Inc.
13G
COAG · 423494103
|
5.1% |
8/7/2026
Event 8/3/2026
|
||||
| Invus Public Equities, L.P. | 4.9% | |||||
| Invus Public Equities Advisors, LLC | 4.9% | |||||
| Invus Global Management, LLC | 4.9% | |||||
| Siren, L.L.C. | 4.9% | |||||
| Avicenna Life Sci Master Fund LP | 0.2% | |||||
| Avicenna Life Sci Master GP LLC | 0.2% | |||||
| Ulys, L.L.C. | 0.2% | |||||
| Raymond Debbane | 5.1% | |||||
|
Agenus Inc.
13G
AGEN · 00847G804
|
10.0% |
7/17/2026
Event 7/13/2026
|
||||
| Invus Public Equities, L.P. | 8.8% | |||||
| Invus Public Equities Advisors, LLC | 8.8% | |||||
| Invus Global Management, LLC | 8.8% | |||||
| Siren, L.L.C. | 8.8% | |||||
| Avicenna Life Sci Master Fund LP | 1.3% | |||||
| Avicenna Life Sci Master GP LLC | 1.3% | |||||
| Ulys, L.L.C. | 1.3% | |||||
| Raymond Debbane | 10.0% | |||||
|
Eloxx Pharmaceuticals, Inc.
13G
ELOX · 29014R301
|
10.0% |
6/15/2026
Event 6/9/2026
|
||||
| Invus Public Equities, L.P. | 8.8% | |||||
| Invus Public Equities Advisors, LLC | 8.8% | |||||
| Invus Global Management, LLC | 8.8% | |||||
| Siren, L.L.C. | 8.8% | |||||
| Avicenna Life Sci Master Fund LP | 1.2% | |||||
| Avicenna Life Sci Master GP LLC | 1.2% | |||||
| Ulys, L.L.C. | 1.2% | |||||
| Raymond Debbane | 10.0% | |||||
|
DBV Technologies S.A.
13G/A
DBVT · 23306J309
|
6.5% |
5/5/2026
Event 3/31/2026
|
||||
| Invus Public Equities, L.P. | 6.1% | |||||
| Invus Public Equities Advisors, LLC | 6.1% | |||||
| Invus Global Management, LLC | 6.1% | |||||
| Siren, L.L.C. | 6.1% | |||||
| Avicenna Life Sci Master Fund LP | 0.4% | |||||
| Avicenna Life Sci Master GP LLC | 0.4% | |||||
| Ulys, L.L.C. | 0.4% | |||||
| Raymond Debbane | 6.5% | |||||
|
Solid Biosciences Inc.
13G/A
SLDB · 83422E204
|
10.0% |
5/5/2026
Event 3/31/2026
|
||||
| Invus Public Equities, L.P. | 8.7% | |||||
| Invus Public Equities Advisors, LLC | 8.7% | |||||
| Invus Global Management, LLC | 8.7% | |||||
| Siren, L.L.C. | 8.7% | |||||
| Avicenna Life Sci Master Fund LP | 1.4% | |||||
| Avicenna Life Sci Master GP LLC | 1.4% | |||||
| Ulys, L.L.C. | 1.4% | |||||
| Raymond Debbane | 10.0% | |||||
|
Tenax Therapeutics, Inc.
13G/A
TENX · 88032L605
|
2.5% |
5/4/2026
Event 3/31/2026
|
||||
| Invus Public Equities, L.P. | 2.1% | |||||
| Invus Public Equities Advisors, LLC | 2.1% | |||||
| Invus Global Management, LLC | 2.1% | |||||
| Siren, L.L.C. | 2.1% | |||||
| Avicenna Life Sci Master Fund LP | 0.4% | |||||
| Avicenna Life Sci Master GP LLC | 0.4% | |||||
| Ulys, L.L.C. | 0.4% | |||||
| Raymond Debbane | 2.5% | |||||
|
Tango Therapeutics, Inc.
13G/A
TNGX · 87583X109
|
4.0% |
5/4/2026
Event 3/31/2026
|
||||
| Invus Public Equities, L.P. | 3.5% | |||||
| Invus Public Equities Advisors, LLC | 3.5% | |||||
| Invus Global Management, LLC | 3.5% | |||||
| Siren, L.L.C. | 3.5% | |||||
| Avicenna Life Sci Master Fund LP | 0.5% | |||||
| Avicenna Life Sci Master GP LLC | 0.5% | |||||
| Ulys, L.L.C. | 0.5% | |||||
| Raymond Debbane | 4.0% | |||||
|
Seer, Inc.
13G/A
SEER · 81578P106
|
4.4% |
5/4/2026
Event 3/31/2026
|
||||
| Invus Public Equities, L.P. | 4.4% | |||||
| Invus Public Equities Advisors, LLC | 4.4% | |||||
| Invus Global Management, LLC | 4.4% | |||||
| Siren, L.L.C. | 4.4% | |||||
| Raymond Debbane | 4.4% | |||||
|
Neumora Therapeutics, Inc.
13G/A
NMRA · 640979100
|
4.7% |
5/4/2026
Event 3/31/2026
|
||||
| Invus Public Equities, L.P. | 4.3% | |||||
| Invus Public Equities Advisors, LLC | 4.3% | |||||
| Invus Global Management, LLC | 4.3% | |||||
| Siren, L.L.C. | 4.3% | |||||
| Avicenna Life Sci Master Fund LP | 0.4% | |||||
| Avicenna Life Sci Master GP LLC | 0.4% | |||||
| Ulys, L.L.C. | 0.4% | |||||
| Raymond Debbane | 4.7% | |||||
|
Bicycle Therapeutics plc
13G/A
BCYC · 088786108
|
3.1% |
5/4/2026
Event 3/31/2026
|
||||
| Invus Public Equities, L.P. | 2.7% | |||||
| Invus Public Equities Advisors, LLC | 2.7% | |||||
| Invus Global Management, LLC | 2.7% | |||||
| Siren, L.L.C. | 2.7% | |||||
| Avicenna Life Sci Master Fund LP | 0.4% | |||||
| Avicenna Life Sci Master GP LLC | 0.4% | |||||
| Ulys, L.L.C. | 0.4% | |||||
| Raymond Debbane | 3.1% | |||||
|
Olema Pharmaceuticals, Inc.
13G
OLMA · 68062P106
|
5.1% |
3/20/2026
Event 3/16/2026
|
||||
| Invus Public Equities, L.P. | 4.5% | |||||
| Invus Public Equities Advisors, LLC | 4.5% | |||||
| Invus Global Management, LLC | 4.5% | |||||
| Siren, L.L.C. | 4.5% | |||||
| Avicenna Life Sci Master Fund LP | 0.6% | |||||
| Avicenna Life Sci Master GP LLC | 0.6% | |||||
| Ulys, L.L.C. | 0.6% | |||||
| Raymond Debbane | 5.1% | |||||
|
Rezolute, Inc.
13G/A
RZLT · 76200L309
|
0% |
2/13/2026
Event 12/31/2025
|
||||
| Invus Public Equities, L.P. | 0% | |||||
| Invus Public Equities Advisors, LLC | 0% | |||||
| Invus Global Management, LLC | 0% | |||||
| Siren, L.L.C. | 0% | |||||
| Avicenna Life Sci Master Fund LP | 0% | |||||
| Avicenna Life Sci Master GP LLC | 0% | |||||
| Ulys, L.L.C. | 0% | |||||
| Raymond Debbane | 0% | |||||
|
enGene Holdings Inc.
13G
ENGN · 29286M105
|
6.3% |
1/27/2026
Event 1/21/2026
|
||||
| Invus Public Equities, L.P. | 5.5% | |||||
| Invus Public Equities Advisors, LLC | 5.5% | |||||
| Invus Global Management, LLC | 5.5% | |||||
| Siren, L.L.C. | 5.5% | |||||
| Avicenna Life Sci Master Fund LP | 0.8% | |||||
| Avicenna Life Sci Master GP LLC | 0.8% | |||||
| Ulys, L.L.C. | 0.8% | |||||
| Raymond Debbane | 6.3% | |||||
|
vTv Therapeutics Inc.
13G/A
VTVT · 918385204
|
9.4% |
11/12/2025
Event 9/30/2025
|
||||
| Invus Public Equities, L.P. | 8.4% | |||||
| Invus Public Equities Advisors, LLC | 8.4% | |||||
| Invus Global Management, LLC | 8.4% | |||||
| Siren, L.L.C. | 8.4% | |||||
| Avicenna Life Sci Master Fund LP | 1.2% | |||||
| Avicenna Life Sci Master GP LLC | 1.2% | |||||
| Ulys, L.L.C. | 1.2% | |||||
| Raymond Debbane | 9.4% | |||||
|
Rani Therapeutics Holdings, Inc.
13G
RANI · 753018100
|
10.0% |
10/23/2025
Event 10/16/2025
|
||||
| Invus Public Equities, L.P. | 8.8% | |||||
| Invus Public Equities Advisors, LLC | 8.8% | |||||
| Invus Global Management, LLC | 8.8% | |||||
| Siren, L.L.C. | 8.8% | |||||
| Avicenna Life Sci Master Fund LP | 1.3% | |||||
| Avicenna Life Sci Master GP LLC | 1.3% | |||||
| Ulys, L.L.C. | 1.3% | |||||
| Raymond Debbane | 10.0% | |||||
|
Bicara Therapeutics Inc.
13G/A
BCAX · 055477103
|
9.6% |
7/31/2025
Event 6/30/2025
|
||||
| Invus Public Equities, L.P. | 8.9% | |||||
| Invus Public Equities Advisors, LLC | 8.9% | |||||
| Invus Global Management, LLC | 8.9% | |||||
| Siren, L.L.C. | 8.9% | |||||
| Avicenna Life Sci Master Fund LP | 0.7% | |||||
| Avicenna Life Sci Master GP LLC | 0.7% | |||||
| Ulys, L.L.C. | 0.7% | |||||
| Raymond Debbane | 9.6% | |||||
|
Inventiva S.A.
13G/A
IVA · 46124U107
|
10.6% |
7/31/2025
Event 6/30/2025
|
||||
| Invus Public Equities, L.P. | 10.6% | |||||
| Invus Public Equities Advisors, LLC | 10.6% | |||||
| Invus Global Management, LLC | 10.6% | |||||
| Siren, L.L.C. | 10.6% | |||||
| Raymond Debbane | 10.6% | |||||
|
Kalaris Therapeutics, Inc.
13G/A
KLRS · 482929106
|
1.5% |
7/29/2025
Event 6/30/2025
|
||||
| Invus Public Equities, L.P. | 1.5% | |||||
| Invus Public Equities Advisors, LLC | 1.5% | |||||
| Invus Global Management, LLC | 1.5% | |||||
| Siren, L.L.C. | 1.5% | |||||
| Raymond Debbane | 1.5% | |||||
|
Vigil Neuroscience, Inc.
13G/A
VIGL · 92673K108
|
4.9% |
2/12/2025
Event 12/31/2024
|
||||
| Invus Public Equities, L.P. | 4.5% | |||||
| Invus Public Equities Advisors, LLC | 4.5% | |||||
| Invus Global Management, LLC | 4.5% | |||||
| Siren, L.L.C. | 4.5% | |||||
| Avicenna Life Sci Master Fund LP | 0.4% | |||||
| Avicenna Life Sci Master GP LLC | 0.4% | |||||
| Ulys, L.L.C. | 0.4% | |||||
| Raymond Debbane | 4.9% | |||||
|
Gossamer Bio, Inc.
13G/A
GOSS · 38341P102
|
2.8% |
2/12/2025
Event 12/31/2024
|
||||
| Invus Public Equities, L.P. | 2.8% | |||||
| Invus Public Equities Advisors, LLC | 2.8% | |||||
| Invus Global Management, LLC | 2.8% | |||||
| Siren, L.L.C. | 2.8% | |||||
| Avicenna Life Sci Master Fund LP | 0% | |||||
| Avicenna Life Sci Master GP LLC | 0% | |||||
| Ulys, L.L.C. | 0% | |||||
| Raymond Debbane | 2.8% | |||||
|
Syros Pharmaceuticals, Inc.
13G/A
SYRS · 87184Q107
|
3.8% |
2/12/2025
Event 12/31/2024
|
||||
| Invus Public Equities, L.P. | 3.8% | |||||
| Invus Public Equities Advisors, LLC | 3.8% | |||||
| Invus Global Management, LLC | 3.8% | |||||
| Siren, L.L.C. | 3.8% | |||||
| Avicenna Life Sci Master Fund LP | 0% | |||||
| Avicenna Life Sci Master GP LLC | 0% | |||||
| Ulys, L.L.C. | 0% | |||||
| Raymond Debbane | 3.8% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.